On September 24, GRAIL, Inc. rose 5.97% in regular trading, trading at $114.925/share, with turnover of $67.12 million. The gain was driven by a landmark favorable vote from the FDA's Medical Devices Advisory Committee on the company's Galleri multi-cancer early detection test.

Specifically, the Molecular and Clinical Genetics Devices Panel's 10 voting members unanimously approved Galleri's safety profile, voted six-to-four in favor of its efficacy, and seven-to-two with one abstention endorsed its benefit-risk profile for detecting multiple cancers in adults aged 50 and older. Prior FDA briefing documents indicated the agency had no major outstanding questions regarding Galleri's analytical performance, bridging analyses, or primary safety results, with discussion focused primarily on product labeling and positioning.

The advisory committee's positive vote lays critical groundwork for a formal FDA approval decision. UBS, which maintains a buy rating with a $105 price target, had previously characterized the risk-reward as attractive, noting that approval could drive the stock toward $150. RBC Capital Markets initiated coverage with an $84 target, citing substantial market potential but flagging adoption and reimbursement hurdles that could temper near-term revenue growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)